CytoDyn Inc. CYDY Archives - Page 3 of 5

ThursdayOct 25, 2018 11:59 am

CytoDyn Inc. (CYDY) Finding Success in Trials of PRO 140 for Treatment of HIV/AIDS; Plans to Expand Clinical Investigations to Cancer

Lead product candidate, PRO 140, is a viral-entry inhibitor that works by blocking the entry of HIV/AIDS to healthy cells by masking CCR5 receptor Completion of Biological License Application (BLA) for potential approval in combination HIV therapy expected in Q1 2019 CytoDyn received approval to increase dosing of PRO 140 in its phase 3 adaptive clinical trial for enrolled HIV/AIDS patients Market potential for PRO 140 as an anti-viral agent in combination with HAART is $1.2 billion; as a monotherapy maintenance/single-drug therapy, the market is estimated at $3.8 billion Acquisition of privately held ProstaGene expected to complete in November, giving…

WednesdayOct 24, 2018 12:35 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Discusses Rapid Clinical Development of PRO 140 in Interview with The Wall Street Transcript

Nader Z. Pourhassan, Ph.D., the president and CEO of CytoDyn (OTCQB: CYDY), was recently interviewed by TWST.com. The interview was highlighted in a recent article titled, “CytoDyn About to Take Off? CEO Nader Pourhassan Ph. D. Says Yes,” which provided an overview of the biotechnology company from the perspective of its president & CEO. Dr. Pourhassan discussed the rapid clinical development of PRO 140 which is being developed as a therapy for HIV. He has overseen PRO 140 from its acquisition to phase II development and phase III trials. In addition, Dr. Pourhassan has been involved in the preclinical and…

ThursdayOct 11, 2018 9:52 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Interim CMO to Present at 11th Annual Conference on Stem Cell and Regenerative Medicine

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence…

TuesdayOct 09, 2018 9:35 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Unveils Development Strategy for PCaTest, Nears Close of Proposed ProstaGene Asset Acquisition

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning detailed its strategy for completing the development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene. Following the completion of its previously announced proposed acquisition of assets from ProstaGene, which is expected to close during the fourth quarter of 2018, CytoDyn intends to initiate a clinical study aimed at further demonstrating the superiority of the PCaTest, as compared with current genetic tests, in predicting outcomes of individuals with prostate cancer. Per the update, results are expected to be available within…

MondayOct 01, 2018 2:48 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Expanding Focus Beyond HIV through Planned Acquisition

CytoDyn (OTCQB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, is now gearing up to further target life-threatening diseases through a potential acquisition. A recent article discussing the company reads, “With its planned acquisition of ProstaGene, LLC, CytoDyn Inc. (OTCQB: CYDY) is expanding its focus beyond HIV and graft-versus-host disease to open up a new front in the fight against cancer. ProstaGene is developing metastasis control technology that targets the chemokine receptor type 5 (CCR5), a protein on the surface of white blood cells. Metastasis is the spread of cancer beyond the original…

ThursdaySep 27, 2018 11:18 am

CytoDyn Inc. (CYDY) to Acquire Biotech Developing Therapies to Stop Cancer from Spreading

CytoDyn signs definitive agreement to acquire privately held ProstaGene Gets access to CCR5 technologies related to cancer Lead candidate PRO 140 set for Investigational New Drug (IND) application in first cancer indication, expanding CytoDyn’s focus beyond HIV With its planned acquisition of ProstaGene, LLC, CytoDyn Inc. (OTCQB: CYDY) is expanding its focus beyond HIV and graft-versus-host disease to open up a new front in the fight against cancer. ProstaGene is developing metastasis control technology that targets the chemokine receptor type 5 (CCR5), a protein on the surface of white blood cells. Metastasis is the spread of cancer beyond the original tumor,…

WednesdaySep 26, 2018 2:01 pm

CytoDyn Inc. (CYDY) Scheduled to Present at The MicroCap Conference on October 1

CytoDyn will present on October 1 at 9 a.m. EST (6 a.m. PST) at The Microcap Conference at the Essex House in New York City, with live webcast available CYDY is a biotechnology company developing humanized monoclonal antibodies for the treatment of multiple therapeutic indications, such as HIV, tumor metastasis and graft-vs-host disease CytoDyn Inc. (OTCQB: CYDY) management is set to present at The Microcap Conference on October 1 at the Essex House in New York at 9 a.m. EST (http://ibn.fm/CEGgV). The MicroCap presentation will be available on live webcast, and a replay will be hosted on the investor’s section of…

ThursdaySep 20, 2018 9:16 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Management Presenting at Two Upcoming Investment Conferences

CytoDyn (OTCQB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, this morning announced that company management is set to present at two upcoming conferences. First, the company will give a presentation at the Fourth Annual Robins Equity Research Roundup in Portland, Oregon on Tuesday, September 25, 2018 at 10:00 a.m. Pacific time. Next, CytoDyn will present at The MicroCap Conference at the Essex House in New York City on Monday, October 1, at 9:00 a.m. ET. A live webcast and replay of the company’s presentation at The MicroCap Conference will be accessible on…

TuesdaySep 18, 2018 12:44 pm

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Highlighted in Corporate Summary from Leading Small Cap Media Portal

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is the focus of a recently-released corporate summary from leading independent small cap media portal EmergingGrowth.com. The update details a number of topics from CytoDyn’s recent shareholder conference call, including highlights from the ongoing clinical development of its PRO 140 viral-entry inhibitor. The EmergingGrowth.com report notes that PRO 140 demonstrated a 93 percent suppression rate in 525mg trials after a six-week induction period. The summary further details CytoDyn’s new monotherapy trial, as well as the company’s recent efforts to generate capital through the sale of shares and the exploration of non-dilutive licensing pathways, particularly…

TuesdaySep 11, 2018 11:37 am

CytoDyn Inc.’s (CYDY) New HIV Treatment Could Bring a Paradigm Shift in HIV Therapy

PRO 140 requires one dose a week, rather than daily pills Treatment has shown hardly any side-effects in clinical trials, while current HIV therapies may cause mild to severe side-effects CytoDyn’s treatment is simple for patients to administer with hardly any toxicity Significant advantages of PRO 140, CytoDyn Inc.’s (OTCQB: CYDY) viral-entry inhibitor, over drugs currently used in HIV treatment therapies have been reported, namely showing little if any toxicity or side-effects in treated patients to date, ease of administration (once weekly dosing) and a lack of HIV resistance developing to the treatment. Although there are several promising HIV therapies…

Site Search

Company Search

Tag: CytoDyn Inc. CYDY